Regulation of p27Kip1 by mitogen-induced tyrosine phosphorylation

Cell Cycle

Volumn 11, Issue 10, 2012, Pages 1910-1917

  Jäkel, Heidelinde ^a   Peschel, Ines ^a   Kunze, Clarissa ^a   Weinl, Christina ^a   Hengst, Ludger ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cyclin dependent kinase inhibitor; Cytokines; Growth factors; JAK2; JAK2V617F; Tyrosine kinases

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 6; JANUS KINASE 2; PROTEASOME; PROTEIN FOS; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; RING FINGER PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; STAT3 PROTEIN; STAT5 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR JUNB; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3; WNT PROTEIN;

BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; ENZYME BINDING; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; EPIGENETICS; ERYTHROLEUKEMIA CELL; FEEDBACK SYSTEM; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LIGAND BINDING; NONHUMAN; ONCOGENE; POINT MUTATION; POSITIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN STRUCTURE; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOSIS; TRANSLATION REGULATION; TUMOR VOLUME; UBIQUITINATION; WNT SIGNALING PATHWAY;

EID: 84861371005     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19957     Document Type: Review

References (92)

1. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71:1286-90; PMID:4524638; http://dx.doi.org/10.1073/pnas.71.4.1286.
2. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002; 1:103-10; PMID:12429916; http://dx.doi.org/10.4161/cc.1.2.108.
3. Merrick KA, Wohlbold L, Zhang C, Allen JJ, Horiuchi D, Huskey NE, et al. Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell 2011; 42:624-36; PMID:21658603; http://dx.doi.org/10.1016/j.molcel.2011.03.031.
4. Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point. Cell Cycle 2006; 5:2281-9; PMID:16969133; http://dx.doi.org/10.4161/cc.5.19.3318.
5. Conradie R, Bruggeman FJ, Ciliberto A, Csikász-Nagy A, Novák B, Westerhoff HV, et al. Restriction point control of the mammalian cell cycle via the cyclin E/Cdk2:p27 complex. FEBS J 2010; 277:357-67; PMID:20015233; http://dx.doi.org/10.1111/j.1742-4658.2009.07473.x.
6. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-67; PMID:18354415; http://dx.doi.org/10.1038/nrc2347.
7. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14:159-69; PMID:18267085; http://dx.doi.org/10.1016/j. devcel.2008.01.013.
8. Kip1interacts with MCM7, a DNA replication licensing factor, to inhibit initiation of DNA replication. FEBS Lett 2005; 579:6529-36; PMID:16289477; http://dx.doi.org/10.1016/j.febslet.2005.10.028.
9. Numata Y, Ishihara S, Hasegawa N, Nozaki N, Ishimi Y. Interaction of human MCM2-7 proteins with TIM, TIPIN and Rb. J Biochem 2010; 147:917-27; PMID:20299328; http://dx.doi.org/10.1093/jb/mvq028.
10. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382:325-31; PMID:8684460; http://dx.doi.org/10.1038/382325a0.
11. Lacy ER, Filippov I, Lewis WS, Otieno S, Xiao L, Weiss S, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol 2004; 11:358-64; PMID:15024385; http://dx.doi.org/10.1038/nsmb746.
12. Otieno S, Grace CR, Kriwacki RW. The role of the LH subdomain in the function of the Cip/Kip cyclin-dependent kinase regulators. Biophys J 2011; 100:2486-94; PMID:21575583; http://dx.doi.org/10.1016/j.bpj.2011.04.014.
13. Schulman BA, Lindstrom DL, Harlow E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci USA 1998; 95:10453-8; PMID:9724724; http:// dx.doi.org/10.1073/pnas.95. 18.10453.
14. Bockstaele L, Bisteau X, Paternot S, Roger PP. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol 2009; 29:4188- 200; PMID:19487459; http://dx.doi.org/10.1128/MCB.01823-08.
15. Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol 2009; 29:986-99; PMID:19075005; http://dx.doi.org/10.1128/MCB.00898-08.
16. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12; PMID:10385618; http://dx.doi.org/10.1101/gad.13.12.1501.
17. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010; 9:689-99; PMID:20107323; http://dx.doi.org/10.4161/cc.9.4. 10611.
18. Ou L, Ferreira AM, Otieno S, Xiao L, Bashford D, Kriwacki RW. Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein. J Biol Chem 2011; 286:30142-51; PMID:21715330; http://dx.doi. org/10.1074/jbc.M111.244095.
19. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006; 24:13-9; PMID:16393691; http://dx.doi.org/10.1080/08977190500361812.
20. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008; 121:3853-7; PMID:19020303; http://dx.doi.org/10. 1242/jcs.039131.
21. Gladden AB, Diehl JA. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005; 96:906-13; PMID:16163738; http://dx.doi.org/10.1002/jcb.20613.
22. Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle 2008; 7:892-8; PMID:18414028; http://dx.doi.org/10.4161/cc.7.7.5637.
23. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10. 1038/nrc2602.
24. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12; PMID:12204530; http://dx.doi.org/10.1016/S1535-6108(02)00102-2.
25. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cell cycle transitions: does one fit all? Nat Rev Mol Cell Biol 2008; 9:910-6; PMID:18813291; http://dx.doi.org/10.1038/nrm2510.
26. 1. Cell 1999; 98:859-69; PMID:10499802; http://dx.doi.org/10.1016/S0092-8674(00)81519-6.
27. Kip1 gene transcription by mitogens. Cell Cycle 2009; 8:115-24; PMID:19158484; http://dx.doi.org/10.4161/cc.8.1.7527.
28. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin- proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-5; PMID:7624798; http://dx.doi.org/10.1126/science.7624798.
29. Kip1accumulation during the cell cycle. Science 1996; 271:1861-4; PMID:8596954; http://dx.doi.org/10.1126/science.271.5257.1861.
30. Fuster JJ, González JM, Edo MD, Viana R, Boya P, Cervera J, et al. Tumor suppressor p27(Kip1) undergoes endolysosomal degradation through its interaction with sorting nexin 6. FASEB J 2010; 24:2998-3009; PMID:20228253; http://dx.doi.org/10.1096/fj.09-138255.
31. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9:2342- 52; PMID:20519948; http://dx.doi.org/10.4161/cc.9.12.11988.
32. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8:438-49; PMID:18500245; http://dx.doi.org/10.1038/nrc2396.
33. Nagano Y, Fukushima T, Okemoto K, Tanaka K, Bowtell DD, Ronai Z, et al. Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress. Cell Cycle 2011; 10:2592-602; PMID:21734459; http:// dx.doi.org/10.4161/cc.10.15.16912.
34. Yung Y, Walker JL, Roberts JM, Assoian RKA. A Skp2 autoinduction loop and restriction point control. J Cell Biol 2007; 178:741-7; PMID:17724117; http:// dx.doi.org/10.1083/jcb.200703034.
35. Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, et al. Altered p27(Kip1) phosphorylation, localization and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. Mol Cell Biol 2002; 22:2993-3002; PMID:11940657; http://dx.doi. org/10.1128/MCB.22.9.2993-3002.2002.
36. kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis. Exp Cell Res 2003; 291:135-49; PMID:14597415; http://dx.doi.org/10.1016/S0014-4827(03)00392-6.
37. kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo. Blood 2005; 105:3691-8; PMID:15665120; http://dx.doi.org/10.1182/blood-2003-07-2558.
38. Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 2003; 278:41355-66; PMID:12904306; http://dx.doi.org/10.1074/jbc.M302830200.
39. Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. J Biol Chem 2004; 279:22498-504; PMID:15010468; http:// dx.doi.org/10.1074/jbc. M400479200.
40. kip1 contributing to actin organization and cortical neuronal migration. Nat Cell Biol 2006; 8:17-26; PMID:16341208; http://dx.doi.org/10.1038/ncb1338.
41. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002; 21:3390-401; PMID:12093740; http://dx.doi.org/10.1093/emboj/cdf343.
42. Kajihara R, Fukushige S, Shioda N, Tanabe K, Fukunaga K, Inui S. CaMKII phosphorylates serine 10 of p27 and confers apoptosis resistance to HeLa cells. Biochem Biophys Res Commun 2010; 401:350-5; PMID:20851109; http://dx.doi.org/10. 1016/j.bbrc.2010.09.051.
43. Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277:28706-13; PMID:12042314; http:// dx.doi.org/10.1074/jbc. M203668200.
44. kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 2005; 26:1021-34; PMID:15718252; http://dx.doi.org/ 10.1093/carcin/bgi050.
45. Kim H, Jung O, Kang M, Lee MS, Jeong D, Ryu J, et al. JNK signaling activity regulates cell-cell adhesions via TM4SF5-mediated p27(Kip1) phosphorylation. Cancer Lett 2012; 314:198-205; PMID:22014979; http://dx.doi.org/10.1016/j.canlet.2011.09.030.
46. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem 2000; 275:25146-54; PMID:10831586; http:// dx.doi.org/10.1074/jbc. M001144200.
47. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20:6672-82; PMID:11726503; http://dx.doi.org/10.1093/emboj/20.23.6672.
48. Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, et al. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003; 14:201-13; PMID:12529437; http:// dx.doi.org/10.1091/mbc.E02-06-0319.
49. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 2003; 23:216-28; PMID:12482975; http://dx.doi.org/10.1128/MCB.23.1.216-28.2003.
50. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization and tumor suppression. Genes Dev 2006; 20:47-64; PMID:16391232; http://dx.doi.org/10.1101/gad.1384406.
51. Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J Biol Chem 2005; 280:1095-102; PMID:15528185; http://dx.doi.org/10.1074/jbc.M406117200.
52. Lee JG, Kay EP. Involvement of two distinct ubiquitin E3 ligase systems for p27 degradation in corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49:189-96; PMID:18172092; http://dx.doi.org/10.1167/iovs.07-0855.
53. Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 2008; 28:6462-72; PMID:18710949; http://dx.doi.org/10.1128/MCB.02300-07.
54. Reynisdóttir I, Massagué J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11:492-503; PMID:9042862; http://dx.doi.org/10.1101/gad. 11.4.492.
55. Zeng Y, Hirano K, Hirano M, Nishimura J, Kanaide H. Minimal requirements for the nuclear localization of p27(Kip1), a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 2000; 274:37-42; PMID:10903892; http://dx.doi.org/10. 1006/bbrc.2000.3098.
56. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009; 8:3455-61; PMID:19829074; http:// dx.doi.org/10.4161/cc.8.21.9789.
57. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9:218-24; PMID:17237771; http://dx.doi.org/10.1038/ncb1537.
58. Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68:5076-85; PMID:18593906; http:// dx.doi.org/10.1158/0008-5472.CAN- 08-0634.
59. Kip1phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci USA 2009; 106:9268-73; PMID:19470470; http://dx.doi. org/10.1073/pnas.0805057106.
60. kip1. EMBO J 2006; 25:5159-70; PMID:17053782; http:// dx.doi.org/10.1038/sj.emboj.7601388.
61. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007; 128:281-94; PMID:17254967; http://dx.doi.org/10.1016/j.cell.2006.11.049.
62. Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 2006; 107:1133-40; PMID:16195327; http://dx.doi.org/10.1182/blood-2005-05-1771.
63. Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007; 128:269-80; PMID:17254966; http://dx.doi.org/10.1016/j.cell.2006.11.047.
64. Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 2008; 28:498-510; PMID:17908796; http://dx.doi.org/10.1128/MCB.02171-06.
65. Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. Oncogene 2011; 30:3502-12; PMID:21423214; http://dx.doi.org/10.1038/onc.2011.68.
66. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999; 287:821-8; PMID:10222191; http://dx.doi.org/10.1006/jmbi.1999.2640.
67. Kato JY, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4- activating kinase. Mol Cell Biol 1994; 14:2713-21; PMID:8139570; http://dx.doi.org/10.1128/MCB.14.4.2713.
68. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93:385-95; PMID:9590173; http://dx.doi.org/10.1016/S0092-8674(00) 81167-8.
69. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26:6724-37; PMID:17934481; http://dx.doi.org/10.1038/sj.onc. 1210757.
70. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102:18962-7; PMID:16365288; http://dx.doi.org/10.1073/pnas.0509714102.
71. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111:3751-9; PMID:18216297; http://dx.doi.org/ 10.1182/blood-2007-07-102186.
72. Halfter H, Friedrich M, Resch A, Kullmann M, Stögbauer F, Ringelstein EB, et al. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1 and cyclin A expression and induced p21 expression. Cancer Res 2006; 66:6530-9; PMID:16818624; http://dx.doi.org/10.1158/0008-5472.CAN-04-3734.
73. kip1 degradation in HepG2 cells. Oncogene 2000; 19:3675-83; PMID:10951574; http://dx.doi.org/10.1038/sj.onc.1203707.
74. Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B, et al. Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem 2004; 279:35486-93; PMID:15123646; http://dx.doi.org/10.1074/jbc.M404202200.
75. Sorenson RL, Stout LE. Prolactin receptors and JAK2 in islets of Langerhans: an immunohistochemical analysis. Endocrinology 1995; 136:4092-8; PMID:7649117; http://dx.doi.org/10.1210/en.136.9.4092.
76. Lobie PE, Ronsin B, Silvennoinen O, Haldosén LA, Norstedt G, Morel G. Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology 1996; 137:4037-45; PMID:8756581; http://dx.doi.org/10.1210/en.137.9.4037.
77. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 1997; 272:17694-702; PMID:9211920; http://dx.doi.org/10. 1074/jbc.272.28.17694.
78. Liu F, Zhao X, Perna F, Wang L, Koppikar P, Abdel- Wahab O, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011; 19:283-94; PMID:21316606; http://dx.doi.org/10.1016/j.ccr.2010.12.020.
79. Dawson MA, Bannister AJ, Göttgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009; 461:819-22; PMID:19783980; http:// dx.doi.org/10.1038/nature08448.
80. Nilsson J, Bjursell G, Kannius-Janson M. Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol Cell Biol 2006; 26:5663-74; PMID:16847321; http:// dx.doi.org/10.1128/MCB.02095-05.
81. Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM, et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 2011; 13:13-21; PMID:21151131; http://dx.doi.org/10.1038/ncb2135.
82. Jamieson CH, Barroga CF, Vainchenker WP. Miscreant myeloproliferative disorder stem cells. Leukemia 2008; 22:2011-9; PMID:18923436; http://dx.doi.org/10.1038/leu.2008.290.
83. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al.; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61; PMID:15781101.
84. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-8; PMID:15793561; http:// dx.doi.org/10.1038/nature03546.
85. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90; PMID:15858187; http://dx.doi.org/10.1056/NEJMoa051113.
86. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673-83; PMID:17721432; http://dx.doi.org/10.1038/nrc2210.
87. Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J, et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008; 112:1960-70; PMID:18559973; http://dx.doi.org/10.1182/ blood-2007-09-113860.
88. Furuhata A, Kimura A, Shide K, Shimoda K, Murakami M, Ito H, et al. p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun 2009; 383:411-6; PMID:19364496; http://dx.doi.org/10.1016/j. bbrc.2009.04.015.
89. 1cyclin- dependent kinases. Genes Dev 1995; 9:1149-63; PMID:7758941; http://dx.doi.org/ 10.1101/gad.9.10.1149.
90. Molatore S, Kiermaier E, Jung CB, Lee M, Pulz E, Höfler H, et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer 2010; 9:116; PMID:20492666; http://dx.doi.org/10. 1186/1476-4598-9-116.
91. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-97; PMID:15837627; http:// dx.doi.org/10.1016/j.ccr.2005.03.023.
92. Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, et al. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Res Treat 2011; 128:69-78; PMID:20669046; http://dx.doi.org/10.1007/s10549-010-1024-7.